A randomized controlled clinical trial of arbidol in patients with acute viral upper respiratory infection

Shi Yi

2005-01-01

Abstract:Objective To determine the efficacy and safety of arbidol in patients with acute viral upper respiratory infection(URI).Methods Patients with URI were divided into two groups according to randomized double-blinded controlled clinical trial principle.Patients in two groups were administrated with arbidol,200mg,tid or ribavirin 150mg,tid for 5 to 7 days respectively.Results 66 patients were enrolled and completed in the study,each group has 33 patients.The rate of cute and efficiency were 27.3% and 97.0% on 4th day and 97.0% and 100% after whole therapy respectively in the study group.The rate of cute and efficiency were 33.3% and 84.9% on 4th day and 78.8% and 90.9% after whole therapy respectively in the control group.There was no significant difference between the two groups(P0.05).Two adverse events were found out in study group.One patient felt moderate thirsty and another felt mild sleepy.These adverse events were disappeared three days later without taken any action.There was no significant difference in the rate of adverse events between the two groups(P0.05).Conclusion Arbidol is an effective and safe medicine for patients with URI.